Press Releases

Share this:
Email

Like this page on Facebook

SU2C and the Dutch Cancer Society Announce New International Translational Research Grant Recipients

SU2C and the Dutch Cancer Society Announce New International Translational Research Grant Recipients

Research efforts will investigate DNA-guided personalized cancer treatment approaches.

PHILADELPHIA — August 2, 2012 - Stand Up To Cancer (SU2C) and the Dutch Cancer Society (KWF Kankerbestrijding), along with the American Association for Cancer Research (AACR), SU2C’s Scientific Partner, announce the recipients of the Sta Op Tegen Kanker International Translational Cancer Research Grant.

Emile E. Voest, M.D., Ph.D., head of the Department of Medical Oncology at the University Medical Center (UMC) Utrecht in the Netherlands, and René Bernards, Ph.D., head of the Division of Molecular Carcinogenesis at the Netherlands Cancer Institute, will lead the research project titled “Prospective Use of DNA-guided Personalized Cancer Treatment” on behalf of the Dutch Center for Personalized Cancer Treatment, a collaborative effort of the three largest cancer centers in the Netherlands: the Netherlands Cancer Institute, Erasmus MC and UMC Utrecht.

“We are extremely pleased with the extraordinary outcomes of the first two Sta Op Tegen Kanker telecasts, and look forward to this fall’s show. It is because of the funds generated by the 2010 show that we are able to fund our first international translational research grant,” said Sung Poblete, Ph.D., R.N., Stand Up To Cancer president and chief executive officer. “This collaboration with the Dutch Cancer Society symbolizes a momentous step in the cancer research arena, one that we know will have an impact on clinical cancer care.”

“It is an innovative step for the Dutch Cancer Society to enhance the collaboration of the most talented and promising researchers across institutes globally, by funding international research teams that will solve key challenges in cancer and have a positive impact on patients in the near future,” commented Michel Rudolphie, the Dutch Cancer Society’s managing director.

The goal of this project is to identify new ways in which DNA analysis can be used to guide the selection of the most appropriate personalized cancer treatments for patients. This research team will focus on “proof-of-principle” studies that include patients from three clinical studies: one on breast cancer and two on colorectal tumors.

The Sta Op Tegen Kanker International Translational Cancer Research Grant provides funding of €1.2 million ($1.4 million U.S.) for four years for this translational cancer research project, which addresses critical problems in patient care, including prevention strategies for those at risk, and delivers near-term patient benefit through investigation by a multidisciplinary, multi-institutional, international team of expert investigators.

The grant is supported with money raised in connection with a November 2010 Dutch version of the Stand Up To Cancer televised fundraising event Sta Op Tegen Kanker, which was broadcast in the Netherlands in cooperation with the Dutch Cancer Society.

 

Research Team Selection Process and Project Information

The proposals for the Sta Op Tegen Kanker International Translational Research Grant project were reviewed by the Dutch Cancer Society Scientific Council in cooperation with the Stand Up To Cancer Scientific Advisory Committee. These Scientific Committees consist of highly accomplished senior laboratory researchers and physician-scientists who are respected internationally for their own accomplishments in cancer research and as leaders in the field.

Each proposal submitted for consideration was reviewed by at least three independent reviewers, experts in the field of the proposal. Based on these reviews, the Dutch Cancer Society’s Scientific Council, in collaboration with Stand Up To Cancer scientific advisors, recommended funding of the team led by Voest and Bernards. The team proposes to develop novel DNA analysis tools to better select cancer patients for specific treatments (i.e., match the right patient to the right drug).

“We urgently need to improve the outcome of clinical trials and be more ambitious for our patients,” Voest said. “We strongly feel that analyzing tumor DNA will not only help us to identify cancer patients that are more likely to respond to a specific anti-cancer drug but also avoid exposing patients to a toxic drug that does not provide benefit. This Stand Up To Cancer grant will allow us to investigate the value of DNA-guided treatment.”

The researchers plan to collect DNA from patients’ tumors both before and two months after the start of defined treatment regimens. They will then correlate the genetic changes in the tumors during that interval with treatment outcome.

Armed with this information, they plan to use state-of-the-art computational biology methods to generate DNA “profiles” that will predict whether patients will respond to a given treatment. By discovering how mutations in tumor DNA are linked to responses to anti-cancer drugs, the team hopes to be able to make far more educated choices for the treatment for individual patients, leading to greater therapeutic benefit, while at the same time reducing the toxicity of noneffective cancer drugs.

“We already have several examples in which the mutation status of the patient is highly predictive for the responses to specific cancer drugs. Through this grant, we will be able to increase our understanding of how the cancer genotype determines how the tumor responds to therapy. As such, we will help expedite the transition to a more individualized treatment for cancer patients,” said Bernards.

The project is estimated to begin Oct. 1, 2012.

 

Principals on the Research Team

The “Prospective Use of DNA-guided Personalized Cancer Treatment” research team consists of a multidisciplinary group of experts. In addition to Voest and Bernards, team members are:

Principals:
• Stefan Sleijfer, M.D., Ph.D., medical oncologist, Erasmus MC, Rotterdam
• Laura van ’t Veer, Ph.D., molecular biologist, University of California San Francisco School of Medicine
• Trey Ideker, Ph.D., computational scientist, pharmaceutical sciences, University of California San Diego

Prior to today’s announcement, Stand Up To Cancer has awarded grants to seven Dream Teams and 26 Innovative Research Grantees who are young investigators. The recipients comprise more than 330 scientists from 68 institutions.

# # #

Media Contacts:

Stand Up To Cancer
Adam Pockriss
(212) 843-8286
.(JavaScript must be enabled to view this email address)

The Dutch Cancer Society (KWF Kankerbestrijding)
Stan Termeer
+ 31 (0) 205700538
S.(JavaScript must be enabled to view this email address)

American Association for Cancer Research
Tara Yates
(215) 446-7110
.(JavaScript must be enabled to view this email address)


About Stand Up To Cancer
Stand Up To Cancer (SU2C) – a program of the Entertainment Industry Foundation (EIF), a 501(c) (3) charitable organization – raises funds to accelerate the pace of groundbreaking translational research that can get new therapies to patients quickly and save lives. SU2C facilitates collaboration among the best and the brightest in the cancer research community. The American Association for Cancer Research (AACR) and a Scientific Advisory Committee conduct rigorous, competitive review processes through which SU2C’s grantees are selected. By galvanizing the entertainment industry, SU2C generates awareness and builds grassroots support for this new approach to ending cancer.

Stand Up To Cancer was founded by a group of media, entertainment and philanthropic leaders whose lives have been affected by cancer in significant ways. Members of SU2C’s Executive Leadership Council include Cancer Advocate and Television Journalist Katie Couric; Sherry Lansing, chairperson of the Entertainment Industry Foundation’s (EIF) Board of Directors and founder of the Sherry Lansing Foundation; EIF President and CEO Lisa Paulsen; EIF Senior Vice President Kathleen Lobb; Rusty Robertson and Sue Schwartz of the Robertson Schwartz Agency; Pamela Oas Williams, President of Laura Ziskin Productions; and nonprofit executive Ellen Ziffren. The late Laura Ziskin, a legendary film producer who executive produced the 2008 and 2010 SU2C telecasts, was also a member of the Executive Leadership Committee. SU2C was formally launched on May 27, 2008. Sung Poblete, Ph.D., R.N., has served as SU2C’s president and CEO since 2011.

For more information, visit www.standup2cancer.org


About the Dutch Cancer Society
The Dutch Cancer Society is a nation-wide organization for cancer-related work in the Netherlands. We spent 80 percent of our budget to finance cancer research; 20 percent is spent to public awareness and information, prevention and patient support programmes. The DCS’ headquarter is located in Amsterdam; our professional staff amount to 140 persons. Over 100,000 volunteers support the Dutch Cancer Society whether it comes to local or nation-wide fundraising, scientific or policy advise in several councils and committees. We could rely on nearly 1,600 local committees that organize our annual door-to-door knocking campaign to raise funds for the fight against cancer (annual revenue around €8 million). The Dutch Cancer Society is supported by 880,000 donors.

The Dutch Cancer Society has been leading the fight against cancer ever since it was founded in 1949. Our goal is less cancer, more cure, and a better quality of life for cancer patients.

About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR’s membership includes 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes seven peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of individual and team science grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer.

For more information about the AACR, visit www.AACR.org.
Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.org

 

Return to Press Releases

Innovate Collaborate Accelerate
There are more than 200 different types of cancer.